Xencor Inc business relationships
Companies named in Xencor Inc’s 10-K filed 2026-02-25, and public companies whose annual reports name Xencor Inc. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 6.1 / 10
- AI naming
- 95 / 100 Top 1% in its category
- Agent readiness
- 30 / 100
- AI adoption
- 0 / 100
Named in Xencor Inc’s annual report 10
“Amgen: In September 2015, we entered into a Research and License Agreement (the "Amgen Agreement") with Amgen to develop and commercialize bispecific antibody product candidates using our proprietary XmAb® bispecific Fc technology.” SEC filing
“In January 2020, the Company entered into a Technology License Agreement (the "Gilead Agreement") with Gilead, pursuant to which the Company granted Gilead an exclusive license to its Cytotoxic Fc and Xtend Fc technologies for an initial identified antibody and options for up to three additional ant...” SEC filing
“Novartis: In June 2016, we entered into a Collaboration and License Agreement (the "Novartis Agreement") with Novartis to develop and commercialize bispecific and other Fc-engineered antibody product candidates using our proprietary XmAb® technologies.” SEC filing
“Novartis: In June 2016, we entered into a Collaboration and License Agreement (the "Novartis Agreement") with Novartis to develop and commercialize bispecific and other Fc-engineered antibody product candidates using our proprietary XmAb® technologies.” SEC filing
“We earned $10.2 million in estimated non-cash royalties from Incyte for the year ended December 31, 2025.” SEC filing
“The change was primarily driven by the revenue recognition associated with Alexion and Incyte license agreements as discussed below.” SEC filing
“Incyte: In June 2010, we entered into a Collaboration and License Agreement with MorphoSys AG, which was subsequently amended in 2012, 2020 and 2024 (as amended, the "MorphoSys Agreement").” SEC filing
“License Agreement with BIO-TECHNE” SEC filing
“Our partnership and license agreements include those we have with J&J, Genentech, Vir, Amgen, Incyte, Alexion and others.” SEC filing
“In August 2020, the Company entered into a Technology License Agreement (the "Omeros Agreement") with Omeros Corporation ("Omeros"), pursuant to which the Company granted Omeros rights to use the Company's Xtend Fc technology for certain antibody product candidates, including zaltenibart.” SEC filing
Companies whose annual reports name Xencor Inc 6
“Tafasitamab licensed from Xencor, Inc.” SEC filing
“Patent License Agreement between the Company and Xencor, Inc., dated March 25, 2020” SEC filing
“...ing solutions and the data generated by our multi-omic technology platform provide value to our biopharma partners, such as Moderna, AbbVie, Xencor, Merck KGaA and Genentech, through partnerships that aim to increase the probability of technical and regulatory success of their therapeutic pipelines.” SEC filing
“entered into a license agreement with Xencor, Inc. ("Xencor"), which has discovered and developed a proprietary biological” SEC filing
“...ted Kingdom, and in the European Union by its licensees pursuant to out-licenses less royalty payments payable by us to Xencor Inc. and (iv) 25% of non-royalty income attributable to obexelimab products payable to us or any of our affiliates by its licensees (other than certain milestone payments pa...” SEC filing
“License Agreements with Xencor, Inc.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.